✦ LIBER ✦

Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis?

✍ Scribed by Kallenberg, C. G. M.

Book ID: 118166434
Publisher: BMJ Publishing Group
Year: 2012
Tongue: English
Weight: 108 KB
Volume: 72
Category: Article
ISSN: 0003-4967
DOI: 10.1136/annrheumdis-2012-202195

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cyclophosphamide treatment in systemic n

Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?

✍ J. H. M. Beimler; K. Andrassy 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 144 KB

Antibodies to endothelial cells in syste

Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis

✍ D. P. D'CRUZ; F. A. HOUSSIAU; G. RAMIREZ; E. BAGULEY; J. McCUTCHEON; J. VIANNA; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 708 KB

Severe Angioedema and Hypocomplementemic

Severe Angioedema and Hypocomplementemic Vasculitis in a Patient with Systemic Lupus Erythematosus (SLE): Rapid Response to IV Cyclophosphamide

✍ Martin, J.C.; Truong, L.D.; Janssen, N.M. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Elevated serum level of growth arrest-sp

Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis

✍ Wu, Chien-Sheng; Hu, Chung-Yi; Tsai, Hwei-Fang; Chyuan, I-Tsu; Chan, Cheng-Ju; C 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 360 KB

Hepatocyte growth factor and transformin

Hepatocyte growth factor and transforming growth factor β1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis

✍ Anna Capuano; Stefano Costanzi; Giusy Peluso; Gianfranco Zannoni; Valerio Gaetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 525 KB

## Abstract ## Objective To determine whether the ratio of hepatocyte growth factor (HGF) to transforming growth factor β1 (TGFβ1) in systemic lupus erythematosus (SLE) nephritis could be a prognostic factor for response to therapy with cyclophosphamide (CYC) and steroids at 6 months, and to exami